Wells Fargo & Company Gossamer Bio, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 400 shares of GOSS stock, worth $428. This represents 0.0% of its overall portfolio holdings.
Number of Shares
400
Previous 1,969
79.69%
Holding current value
$428
Previous $2,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding GOSS
# of Institutions
101Shares Held
175MCall Options Held
453KPut Options Held
543K-
Nea Management Company, LLC Timonium, MD18.1MShares$19.4 Million1.54% of portfolio
-
Artal Group S.A. Luxembourg, N413.3MShares$14.2 Million0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$12.6 Million0.0% of portfolio
-
Octagon Capital Advisors LP New York, NY9.19MShares$9.83 Million1.91% of portfolio
-
Arch Venture Management, LLC Chicago, IL8.06MShares$8.62 Million4.25% of portfolio
About Gossamer Bio, Inc.
- Ticker GOSS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,954,000
- Market Cap $101M
- Description
- Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...